Kodiak Sciences shares soar after eye drug succeeds in late-stage study

By Siddhi Mahatole March 26 (Reuters) - Shares of Kodiak Sciences surged 68.6% to their highest in more than four years on Thursday after the drug developer's experimental drug met the main goal in a late-stage study in patients with diabetes-related eye damage. Kodiak, valued at $1.39 billion as of Wednesday's close, was testing the drug, Zenkuda, to treat diabetic retinopathy - an eye